NEW YORK (GenomeWeb News) – Drug firm Summit and the Children's National Medical Center in Washington today announced a collaboration for the development of a proteomic assay to measure biomarkers in support of Summit's candidate drug for Duchenne Muscular Dystrophy (DMD).

Under the terms of the deal, Yetrib Hathout, a principal investigator at CNMC's Center for Genetic Medicine Research, will develop a mass spectrometry-based assay to measure levels of a protein called utrophin in DMD muscle that may prove useful in treating the disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.